Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 287 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: magnesium stearate; gelatin; titanium dioxide; purified talc - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate, quantity: 52.05 mg (equivalent: doxycycline, qty 50 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; hydrogenated castor oil; povidone - infections caused by the following micro-organisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always elminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline, or in combination with topical agents.) borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). doxycycline sandoz is indicated for the treatment of anthrax due to bacillus anthracis, including inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis (see dosage and administration). infections caused by the following gram-negative micro-organisms: vibrio sp. (cholera); brucella sp. (brucellosis; in conjunction with streptomycin); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteriodes sp. when penicillin is contraindicated, doxycycline is an alternative medicine in the treatment of infections due to: treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). note: doxycycline sandoz is not the medicine of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline sandoz should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual medicine of choice. in acute intestinal amoebiasis doxycycline sandoz may be a useful adjunct to amoebicides. in severe acne doxycycline may be a useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by plasmodium vivax. as there are relatively few locations where p. vivax does not coexist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate, quantity: 104.1 mg (equivalent: doxycycline, qty 100 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; hydrogenated castor oil; povidone; magnesium stearate - infections caused by the following micro-organisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always elminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline, or in combination with topical agents.) borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). doxycycline sandoz is indicated for the treatment of anthrax due to bacillus anthracis, including inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis (see dosage and administration). infections caused by the following gram-negative micro-organisms: vibrio sp. (cholera); brucella sp. (brucellosis; in conjunction with streptomycin); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteriodes sp. when penicillin is contraindicated, doxycycline is an alternative medicine in the treatment of infections due to: treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). note: doxycycline sandoz is not the medicine of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline sandoz should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual medicine of choice. in acute intestinal amoebiasis doxycycline sandoz may be a useful adjunct to amoebicides. in severe acne doxycycline may be a useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by plasmodium vivax. as there are relatively few locations where p. vivax does not coexist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 50 mg/ml - oral liquid, powder for - excipient ingredients: colloidal anhydrous silica; silicon dioxide; disodium edetate; sodium benzoate; xanthan gum; saccharin sodium; sorbitol; flavour - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 25 mg/ml - oral liquid, powder for - excipient ingredients: colloidal anhydrous silica; silicon dioxide; disodium edetate; sodium benzoate; xanthan gum; saccharin sodium; sorbitol; flavour - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - amoxycillin as amoxycillin trihydrate - parenteral liquid/solution/suspension - amoxycillin as amoxycillin trihydrate antibiotic active 150.0 mg/ml - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - antibiotics - oral, parenteral | bacillus anthracis | bacterial infection | bordetella bronchiseptica | clostridium spp. | corynebacterium spp. | escherichia coli (e. coli) | fusobacterium spp. | proteus mirabilis | salmonella spp. | staphylococcus - not penicillin resist | streptococci | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacteria | anaerobic bacterial infection | anthrax | associated with viral disease | avian mycoplasmas | bacterial canker | canine cough syndrome | clavulanic acid sensitive | clostridium botulinum | clostridium chauvoei | clostridium fallax | clostridium feseri | clostridium hemolyticum | clostridium novyi | clostridium perfringens types | clostridium septicum | clostridium sordelli | clostridium sporogenes | clostridium tetani | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | excluding penicillin resistant | gentamicin sensitive | gram negative organisms | gram positi

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

energique, inc. - baptisia tinctoria root (unii: 5ef0hwi5wu) (baptisia tinctoria root - unii:5ef0hwi5wu), echinacea angustifolia (unii: vb06av5us8) (echinacea angustifolia - unii:vb06av5us8), bacillus anthracis immunoserum rabbit (unii: 41lz22dd4n) (bacillus anthracis immunoserum rabbit - unii:41lz22dd4n), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), crotalus horridus horridus venom (unii: yha2xlj956) (crotalus h - baptisia tinctoria root 3 [hp_x] in 1 ml - for temporary relief of septic states, venomous infection, blood poisoning/blood disorders, fever, muscular soreness, burning/stinging pain, convulsions, inflammation, gangrene and/or paralysis.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. for temporary relief of septic states, venomous infection, blood poisoning/blood disorders, fever, muscular soreness, burning/stinging pain, convulsions, inflammation, gangrene and/or paralysis.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; macrogol 4000; hypromellose; maize starch; sodium starch glycollate; magnesium stearate; titanium dioxide; purified talc - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; purified talc; hypromellose; macrogol 4000; titanium dioxide; maize starch; sodium starch glycollate; magnesium stearate - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; maize starch; purified talc; titanium dioxide; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; hypromellose; macrogol 4000 - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.